Central and Southern Asia vs Cyprus: Percentage of bloodstream infection due to methicillin-resistant
Central and Southern Asia
61.0%
in 2022
Cyprus
55.9%
in 2022
Central and Southern Asia rank
2nd
Cyprus rank
5th
Percentage of bloodstream infection due to methicillin-resistant over time
- Central and Southern Asia
- Cyprus
How they compare
Central and Southern Asia currently reports 61.0% against 55.9% in Cyprus, a difference of 5.1%.
That makes Central and Southern Asia's figure about 1.1 times Cyprus's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Central and Southern Asia ahead.
Central and Southern Asia ranks 2nd and Cyprus ranks 5th of 15 groups.
Across the 2 decades both report, Central and Southern Asia averaged higher in 1 and Cyprus in 1.
Head to head by decade
| Decade | Central and Southern Asia | Cyprus | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 45.3% | 57.1% | 11.9% | Cyprus |
| 2020s | 56.6% | 49.5% | 7.2% | Central and Southern Asia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to methicillin-resistant, Central and Southern Asia or Cyprus?
- Central and Southern Asia, at 61.0% against 55.9% in Cyprus as of 2022.
- What is the difference in percentage of bloodstream infection due to methicillin-resistant between Central and Southern Asia and Cyprus?
- 5.1%, with Central and Southern Asia ahead.
- How many years of comparable data are there for Central and Southern Asia and Cyprus?
- 6 years are reported by both, from 2017 to 2022.
- How do Central and Southern Asia and Cyprus rank globally for percentage of bloodstream infection due to methicillin-resistant?
- Central and Southern Asia ranks 2nd and Cyprus ranks 5th of 15 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.